Xu GL - Search Results

1

Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.

Jia WD, Zhang CH, Xu GL, Ge YS, Wang W. Jia WD, et al. Among authors: xu gl. Hepatogastroenterology. 2010 Mar-Apr;57(98):292-9. Hepatogastroenterology. 2010. PMID: 20583430 Review.

2

Octreotide acts as an antitumor angiogenesis compound and suppresses tumor growth in nude mice bearing human hepatocellular carcinoma xenografts.

Jia WD, Xu GL, Xu RN, Sun HC, Wang L, Yu JH, Wang J, Li JS, Zhai ZM, Xue Q. Jia WD, et al. Among authors: xu gl, xu rn. J Cancer Res Clin Oncol. 2003 Jun;129(6):327-34. doi: 10.1007/s00432-003-0447-5. Epub 2003 Jun 14. J Cancer Res Clin Oncol. 2003. PMID: 12811549

3

Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo.

Jia WD, Xu GL, Sun HC, Wang L, Xu RN, Xue Q. Jia WD, et al. Among authors: xu gl, xu rn. Hepatobiliary Pancreat Dis Int. 2003 Aug;2(3):404-9. Hepatobiliary Pancreat Dis Int. 2003. PMID: 14599948

4

Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma.

Wang W, Jia WD, Xu GL, Wang ZH, Li JS, Ma JL, Ge YS, Xie SX, Yu JH. Wang W, et al. Among authors: xu gl. Dig Dis Sci. 2009 Oct;54(10):2128-36. doi: 10.1007/s10620-008-0605-3. Epub 2008 Dec 4. Dig Dis Sci. 2009. PMID: 19052864

5

Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Zhang CH, Xu GL, Jia WD, Ge YS. Zhang CH, et al. Among authors: xu gl. Int J Cancer. 2009 Jun 15;124(12):2982-8. doi: 10.1002/ijc.24311. Int J Cancer. 2009. PMID: 19296539

6

A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice.

Jia WD, Xu GL, Wang W, Wang ZH, Li JS, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB. Jia WD, et al. Among authors: xu gl. Tohoku J Exp Med. 2009 Jun;218(2):155-60. doi: 10.1620/tjem.218.155. Tohoku J Exp Med. 2009. PMID: 19478472 Free article.

7

[Effects of high metastatic potential hepatocellular carcinoma cell-binding peptide on the invasion and metastasis of liver cancer].

Jia WD, Wang W, Tang ZY, Xu GL, Sun HC, Zhou HJ. Jia WD, et al. Among authors: xu gl. Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):241-5. Zhonghua Zhong Liu Za Zhi. 2009. PMID: 19615273 Chinese.

8

Can hepatocellular carcinoma be treated by Yondelis through targeting both tumor cells and tumor-associated macrophages?

Zhang CH, Xu GL, Jia WD, Ge YS, Wang W. Zhang CH, et al. Among authors: xu gl. Hepatogastroenterology. 2010 Jan-Feb;57(97):114-6. Hepatogastroenterology. 2010. PMID: 20422884 Review.

9

Prognostic significance and mechanisms of patterned matrix vasculogenic mimicry in hepatocellular carcinoma.

Liu WB, Xu GL, Jia WD, Li JS, Ma JL, Chen K, Wang ZH, Ge YS, Ren WH, Yu JH, Wang W, Wang XJ. Liu WB, et al. Among authors: xu gl. Med Oncol. 2011 Dec;28 Suppl 1:S228-38. doi: 10.1007/s12032-010-9706-x. Epub 2010 Oct 19. Med Oncol. 2011. PMID: 20957524

10

Extracellular matrix protein 1, a novel prognostic factor, is associated with metastatic potential of hepatocellular carcinoma.

Chen H, Jia WD, Li JS, Wang W, Xu GL, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB, Zhang CH, Wang YC. Chen H, et al. Among authors: xu gl. Med Oncol. 2011 Dec;28 Suppl 1:S318-25. doi: 10.1007/s12032-010-9763-1. Epub 2010 Dec 3. Med Oncol. 2011. PMID: 21128013

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

453 results

Search Page

Filters